id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-0682-0006,FDA,FDA-2022-E-0682,Determination of Regulatory Review Period for Purposes of Patent Extension; BYLVAY,Notice,Determinations,2024-12-18T05:00:00Z,2024,12,2024-12-18T05:00:00Z,2025-02-19T04:59:59Z,2025-02-20T02:00:26Z,2024-29966,0,0,090000648687b924
FDA-2022-E-0682-0005,FDA,FDA-2022-E-0682,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-11-01T04:00:00Z,2024,11,2024-11-01T04:00:00Z,,2024-11-01T13:34:05Z,,0,0,09000064867ec9ef
FDA-2022-E-0682-0004,FDA,FDA-2022-E-0682,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2024-03-18T19:11:34Z,,0,0,09000064864796ff
FDA-2022-E-0682-0003,FDA,FDA-2022-E-0682,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2024-01-19T05:00:00Z,2024,1,2024-01-19T05:00:00Z,,2024-01-19T21:50:10Z,,0,0,09000064863ae6f2